Amylyx Pharmaceuticals, Inc. (AMLX)
| Market Cap | 1.98B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -150.11M |
| Shares Out | 111.19M |
| EPS (ttm) | -1.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,562,163 |
| Open | 17.41 |
| Previous Close | 17.44 |
| Day's Range | 17.15 - 18.03 |
| 52-Week Range | 5.97 - 18.74 |
| Beta | -0.16 |
| Analysts | Strong Buy |
| Price Target | 24.40 (+37.16%) |
| Earnings Date | Aug 6, 2026 |
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phas... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for AMLX stock is "Strong Buy." The 12-month stock price target is $24.4, which is an increase of 37.16% from the latest price.
News
Amylyx price target raised to $40, named a Best Idea at Guggenheim
Guggenheim raised the firm’s price target on Amylyx (AMLX) to $40 from $30 and keeps a Buy rating on the shares, which are also elevated to the analyst’s “Best Idea”…
Amylyx to present data from first-in-human, dose-ranging Phase 1 Lumina trial
Amylyx (AMLX) Pharmaceuticals announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European Network to Cure ALS Meeting 2026, held from June…
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026.
Amylyx Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Avexitide, a GLP-1 receptor antagonist for PBH, is in phase III with results expected in Q3. Commercial launch is targeted for 2027, supported by strong prior data, robust trial design, and a rare disease-focused strategy. Pipeline includes a long-acting GLP-1 antagonist and an ALS therapy.
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026.
Amylyx Pharmaceuticals Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved by stockholders. No questions were raised, and voting results will be filed with the SEC.
Amylyx announces publication of Phase 2 open-label HELIOS trial data
Amylyx (AMLX) Pharmaceuticals announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taur...
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical ...
Amylyx Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
AVEXITIDE is nearing pivotal phase III data for PBH, with strong prior efficacy and minimal expected placebo effect. Commercial plans target 160,000 U.S. patients, with a 2027 launch anticipated and cash runway into 2028. Expansion includes a long-acting version and pipeline assets for rare diseases.
Amylyx sees cash runway into 2028
Cash, cash equivalents, and short-term investments were $279.8 million at March 31, 2026, compared to $317.0 million at December 31, 2025. Based on its current operating plans, Amylyx (AMLX) expects…
Amylyx Pharmaceuticals Earnings Call Transcript: Q1 2026
Advanced pivotal LUCIDITY trial for avexitide in PBH, with top-line data expected next quarter and NDA preparations underway. Q1 operating expenses rose 16% year-over-year, with a strong cash position supporting a potential 2027 launch. Expanded access and commercial readiness efforts are progressing.
Amylyx Pharmaceuticals Earnings release: Q1 2026
Amylyx Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Amylyx Pharmaceuticals Quarterly report: Q1 2026
Amylyx Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results.
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences.
Amylyx announces launch of U.S. EAP for adults with PBH
Amylyx (AMLX) Pharmaceuticals announced the launch of a U.S. Expanded Access Program, EAP, for up to 250 adults with post-bariatric hypoglycemia, PBH, to provide treatment access to avexitide, an inve...
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the launch of a U.S. Expanded Access Program (EAP) for up to 250 adults with ...
Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026.
Amylyx price target raised to $21 from $19 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Amylyx (AMLX) to $21 from $19 and keeps an Outperform rating on the shares ahead of the Q1 report. The…
Amylyx Pharmaceuticals Proxy statement: Proxy filing
Amylyx Pharmaceuticals filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Amylyx Pharmaceuticals Proxy statement: Proxy filing
Amylyx Pharmaceuticals filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Amylyx Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
Avexitide, a GLP-1 antagonist for post-bariatric hypoglycemia, is in phase III trials with results expected in Q3 2025. Prior studies showed a 64% reduction in severe hypoglycemic events, and the company is targeting a 2027 launch for this first-in-class therapy.
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference.
Amylyx completes enrollment in Phase 3 Lucidity trial of avexitide
Amylyx (AMLX) Pharmaceuticals announced that the last participant has been randomized and dosed in the Phase 3 Lucidity clinical trial of avexitide. Lucidity is a 16-week, multicenter, randomized, dou...